Allogeneic Transplantation for Solid Tumors

Transcription

1 3 rd ATST Meeting Allogeneic Transplantation for Solid Tumors Santa Maria della Scala Museum Siena - March 28 th, 2008 Under the auspices of Associazione Italiana di Oncologia Medica - Section Care - Section Conferences

2 GENERAL INFORMATION MEETING VENUE Santa Maria della Scala Museum Piazza Duomo 2 - Siena, Italy SCIENTIFIC COMMITTEE Marco Bregni San Raffaele Scientific Institute [email protected] Richard W. Childs National Institutes of Health [email protected] Naoto T. Ueno M.D. Anderson Cancer Centre [email protected] ORGANISING SECRETARIAT San Raffaele Congress Centre Via Olgettina Milano, Italy Phone: Fax: [email protected] C.M.E. - CONTINUOUS MEDICAL EDUCATION The Italian Ministry of Health will be requested to evaluate the meeting for C.M.E. The credits will be reserved only to Italian specialists in Haematology, Oncology and Pediatrics. REGISTRATIONS To register for the meeting, please send the enclosed form, duly filled in, to the Organising Secretariat, together with the proof of payment. Registration fee covers participation to the scientific sessions, attendance certificate, welcome dinner and catering service during the meeting. WELCOME DINNER Welcome dinner will be held on Thursday evening, March 27 th, at Enoteca Italiana, the public institution founded in 1960 with the aim of promoting Italian wines, established within the premises of the sixteenth century Medici Fortress. Dinner is included in the delegates registration fee; accompanying persons should attend by paying 96,00 (VAT 20% included).

3 INTRODUCTION Tn association with the EBMT Solid Tumor Working Party, we are pleased to invite you to attend the 3 rd International Allogeneic Transplantation for Solid Tumors (ATST) meeting in Siena, Italy on March 28 th, This one day meeting will be held at the charming medieval Santa Maria della Scala Museum, formerly one of European oldest hospitals. The town of Siena is approximately a 40 minute car drive from Florence, where the 34 th annual EBMT meeting will commence, following the ATST meeting, on March 30 th, Over the past 10 years, investigators across the world have pursued investigational trials of reduced intensity allogeneic hematopoietic cell transplantation for a number of metastatic tumors to test whether the graft-vs-leukemia effect could be extended to tumors of epithelial origin. Case reports of solid tumors regressing months after the conditioning regimen have provided proof of concept of the existence of a graft-vs-solid tumor effect. Importantly, some patients with renal cell carcinoma and breast cancer achieved complete responses which persist more than 5 years after transplantation, suggesting this immune effect may have the potential to cure. The 3 rd ATST meeting will update results on allogeneic transplantation for solid tumors, highlighting the collected experience with metastatic renal cell carcinoma, breast carcinoma, and colon cancer. Although reduced intensity regimens have proven to be feasible and associated with limited toxicities, new strategies that enhance the allogeneic anti-tumor response appear to be a promising area of research. Approximately sixteen world renowned experts in the field of tumor immuno-biology and allogeneic transplantation have been invited to speak on methods to enhance graft-vs-tumor effects utilizing tumor antigen specific T-cells, alloreactive NK cells, and post transplant tumor vaccine approaches. Bench to bedside studies investigating adoptive donor NK cells infusions to enhance graft-vs-solid tumor effects and the recent discovery of several new tumor antigens overexpressed on cancer cells identified using T-cells from responding transplant patients will be reviewed. Preclinical data evaluating transplant approaches that incorporate drugs inhibiting tumor angiogenesis and tyrosine kinases with activity against kidney cancer and breast carcinoma will be reviewed. The final portion of the programme will be dedicated to constructing an international solid tumor transplant consortium to pursue multi-center studies investigating novel allogeneic immunotherapy protocols for solid tumors. Meeting attendees are invited and encouraged to submit and present an overview of proposed transplant protocols for consideration of sponsorship by this consortium. Marco Bregni Richard W. Childs Naoto T. Ueno

4 SCIENTIFIC PROGRAMME Introduction to ATST-3 and Meeting Objectives N.T. Ueno LECTURE SESSION 1 Allogeneic Immunotherapy for Renal Cell Cancer Chairpersons: J.A. Barrett and W. Herr Combining mtor and tyrosine kinase inhibitors with allogeneic immunotherapy for RCC - Impact on immune responses P. Brossart 2. Identification of new RCC tumor antigens using allogeneic T-cells R.W. Childs 3. Adoptive NK infusions to boost graft-vs-rcc responses: from mouse to man A.E.L. Lundqvist 4. Update on allogeneic transplantation for RCC M. Bregni LECTURE SESSION 2 Allogeneic Immunotherapy for Breast Cancer Chairpersons: D. Niederwieser and T. Teshima Animal models of allogeneic transplantation for Breast Cancer. Lessons learned and new methods to augment GVT effects S. Slavin 2. VEGF inhibition to enhance graft-vs-tumor responses M.M. Dikov 3. Enhancing NK cell activity against Breast Cancer M.W. Lowdell 4. Can allogeneic transplantation cure metastatic Breast Cancer? Clinical updates and results of a new meta analysis N.T. Ueno

5 LECTURE SESSION 3 Allogeneic Immunotherapy for Colon Cancer Chairpersons: M. Aglietta and O. Ringdén Modification of natural history of metastatic colon cancer with patient-targeted modern therapies S. Siena 2. Combined liver and allogeneic stem cell transplantation for large primary liver cancer O. Ringdén 3. Directing donor T-cells against CEA and survivin after transplantation to augment GVT D. Sangiolo LECTURE SESSION 4 Graft-versus-tumor effect in pediatric solid tumors Chairpersons: F. Fagioli and F. Porta KIR-HLA receptor ligand mismatch enhances graft versus tumor effect in haploidentical stem cell transplantation in pediatric metastatic solid tumors A. Pérez Martínez 2. Haploidentical transplantation using CD3/19 depleted stem cells in children with refractory solid tumors R. Handgretinger LECTURE SESSION 5 Development of a Solid Tumor Transplant Consortium to systematically investigate novel allogeneic immunotherapy regimens for select solid tumors in the multi-center setting Chairpersons: M. Bregni and R.W. Childs Project overview: conceptual multi-center design and funding M. Bregni and R.W. Childs 2. Funding mechanisms to support a European/American Solid Tumor Consortium P. Blaes and S. Giralt 3. Review of proposed protocols: open presentations

6 FACULTY Massimo Aglietta Institute for Cancer Research and Treatment Candiolo - Torino, Italy John A. Barrett National Institutes of Health Bethesda - Maryland, USA Pascale Blaes ESMO - European Society for Medical Oncology Brussels, Belgium Marco Bregni San Raffaele Scientific Institute Milano, Italy Peter Brossart University of Bonn Bonn, Germany Richard W. Childs National Institutes of Health Bethesda - Maryland, USA Mikhail M. Dikov Vanderbilt University Nashville - Tennessee, USA Franca Fagioli Università degli Studi di Torino Torino, Italy Sergio Giralt M.D. Anderson Cancer Centre Houston - Texas, USA Rupert Handgretinger University Hospital of Tübingen Tübingen, Germany Wolfgang Herr University Hospital Mainz Mainz, Germany Mark W. Lowdell Royal Free & University College London, UK Andreas E.L. Lundqvist National Institutes of Health Bethesda - Maryland, USA Antonio Pérez Martínez Hospital Niño Jesús Madrid, Spain Dietger Niederwieser Universität Leipzig Leipzig, Germany Fulvio Porta Ospedale dei Bambini Brescia, Italy Olle Ringdén Karolinska University Hospital Huddinge - Stockholm, Sweden Dario Sangiolo Institute for Cancer Research and Treatment Candiolo - Torino, Italy Salvatore Siena Ospedale Niguarda Ca Granda Milano, Italy Shimon Slavin International Center for Cell Therapy & Cancer immunotherapy Tel Aviv, Israel Takanori Teshima Kyushu University Hospital Fukuoka, Japan Naoto T. Ueno M.D. Anderson Cancer Centre Houston - Texas, USA

7 HOTEL ACCOMMODATION Athena Jolly La Colonna San Marco Hotel**** Hotel**** Hotel*** Hotel*** Contact person Ms Serena Bianciardi Ms Aline Modena Ms Loriana Codogno Ms Sara Sangiorgi Ms Noemi Palla Ms Chiara Pagni Address Via P. Mascagni 55 Piazza La Lizza Strada di Pescaia 73/75 Via Massetana 70 Phone number Fax number address Web-site Double room 155,00 Superior (single use) rate 199,00 Deluxe 160,00 80,00 95,00 Double room rate 180,00 Superior 250,00 Deluxe 180,00 110,00 115,00 Notes Downtown and walking Downtown and 15 distance from the 15 distance from the distance from the walking distance from congress venue by congress venue by congress venue the congress venue free shuttle service free shuttle service The above mentioned hotels have reserved an allotment of rooms for the 3 rd ATST Meeting. All participants interested in making a reservation, should contact the preferred hotel directly, referring to the ATST Group, before January 25 th, Please be informed that the number of rooms reserved is limited; requests of accommodation will be granted on a first come, first served basis. HOW TO REACH SIENA By bus From Firenze - (Regione Toscana - Line Firenze/Siena) SITA Bus Station next to Santa Maria Novella Railway Station - Bus Siena Rapida By train Once arrived at Firenze S. Maria Novella Station take the bus Siena Rapida - By plane From Firenze Amerigo Vespucci Airport - Train to Firenze S. Maria Novella Railway Station and then bus Siena Rapida From Pisa Galileo Galilei Airport - Daily shuttle-bus by reservation - Journey time in 2h. - Train to Firenze S. Maria Novella Railway Station and then bus "Siena Rapida" By car From Northern Italy Motorway A1 exit Firenze Certosa - Highway Firenze-Siena - Exit Siena Nord From Southern Italy Motorway A1 exit Valdichiana - Highway 326 to Siena - Exit Siena Nord

8 On the cover: Domenico Di Bartolo - XV Century Care of the infirm (detail) Santa Maria della Scala Museum